Pharmaceutical Research Center This application seeks to continue the evolution of the Pharmaceutical Research Center at Florida A&M University (FAMU). The previously funded targeted research activities have demonstrated productivity and resulted in significant discoveries that have led to the award of several patents and additional pending discoveries. Based on the evaluation of the current research infrastructure and the strategic needs of the program, it is proposed to transition the targeted activities into the development of Core research facilities. The main objective of the current application is to build the infrastructure of the research program towards more understanding of the mechanistic details of the molecular system. This RCMI center will focus efforts on approaches, i.e., gene expression analysis, proteomics, PCR analysis, gene delivery systems and DNA microarray techniques. The establishment of Core facilities in the areas of molecular neurobiology, cellular imaging, neurochemistry/receptors, flow cytometery and nanomedicine will increase our abilities to understand the mechanistic details of the molecular system and to provide greater insights into how the different molecular are modulated under disease and adverse conditions. The Pharmaceutical Research Center will consist of a research administrative component coupled with four (4) core service delivery facilities. The administrative component will continue to provide pre- and post- award assistance, coordinate Ithe activities of the external and internal advisory committee, provide scientific seminars and grants workshops, coordinate a new structured mentoring program, facilitate an extensive external evaluation of program outcomes, assist in faculty development, hire a research faculty member and market and conduct an on-site grants management workshop and the annual RCMI R01 Scientist Seminar Series. Specif aim one (1) is to transition the program from the current research programs in neuroscience, drug delivery, and molecular biology to research cores focusing on Neurodegeneration research, Nanomedicine research, drug discovery and biotechnology: pathways to disease prevention and therapy. Through this network of Core facilities, the Pharmaceutical Research Center will foster inter- and inter-disciplinary research.
Aim two (2) is to increase research investigators capabilities and competitiveness to receive four (4) investigators initiated grants.
Aim three (3) is to assure the completion of program objectives and outcomes through a comprehensive formative and summative evaluation process.
Aim four (4) is to address health disparities through research emphasis on those conditions that adversely impact disadvantaged populations and produce additional minority scientists who will address disparities. This RCMI Program has been transformational at FAMU. Ensuring translational research is at the forefront of the proposed research activities as we seek to accelerate the utilization of our biomedical discoveries. The College's motto is "Funding Cures and Saving Lives."

National Institute of Health (NIH)
National Institute on Minority Health and Health Disparities (NIMHD)
Research Centers in Minority Institutions Award (G12)
Project #
Application #
Study Section
Special Emphasis Panel (ZRR1-RI-3 (01))
Program Officer
Mcclure, Shelia A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Florida Agricultural and Mechanical University
Schools of Pharmacy
United States
Zip Code
Odewumi, Caroline O; Fils-Aime, Shiela; Badisa, Veera L D et al. (2015) Chemoprotective effect of monoisoamyl 2, 3-dimercaptosuccinate (MiADMS) on cytokines expression in cadmium chloride treated human lung cells. Environ Toxicol 30:704-11
Eyunni, Suresh Kumar V K; Gangapuram, Madhavi; Redda, Kinfe K (2014) In-vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models. Lett Drug Des Discov 11:428-436
Sampson, Dinithia; Zhu, Xue Y; Eyunni, Suresh V K et al. (2014) Identification of a new selective dopamine D4 receptor ligand. Bioorg Med Chem 22:3105-14
Bauer, David; Mazzio, Elizabeth; Soliman, Karam Fa et al. (2014) Diallyl disulfide inhibits TNF?-induced CCL2 release by MDA-MB-231 cells. Anticancer Res 34:2763-70
Green, Jennifer E; Cooperwood, John S; Taka, Equar et al. (2014) Comparative proteomic analysis reveals growth inhibition by 3-N-alkyloxyestradiol derivative (SERM) in prostate cancer cells. Cancer Genomics Proteomics 11:195-200
Badisa, Ramesh B; Fitch-Pye, Cheryl A; Agharahimi, Maryam et al. (2014) Milk thistle seed extract protects rat C6 astroglial cells from acute cocaine toxicity. Mol Med Rep 10:2287-92
Aguilar, Byron J; Nkembo, Augustine T; Duverna, Randolph et al. (2014) Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer. Eur J Med Chem 81:323-33
Bricker, Barbara; Sampson, Dinithia; Ablordeppey, Seth Y (2014) Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument. Pharmacol Biochem Behav 120:109-16
Sampson, Dinithia; Bricker, Barbara; Zhu, Xue Y et al. (2014) Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett 24:4294-7
Ayuk-Takem, Lambert; Amissah, Felix; Aguilar, Byron J et al. (2014) Inhibition of polyisoprenylated methylated protein methyl esterase by synthetic musks induces cell degeneration. Environ Toxicol 29:466-77

Showing the most recent 10 out of 35 publications